CAS: 1245792-51-1

BCI

BCI ((E)-BCI) is an allosteric inhibitor of dual-specificity phosphatase (DUSP; EC50s: 13.3 and 8.0 μM for DUSP6 and DUSP1 in cells) and does not inhibit DUSP5.

(E)-2-Benzylidene-3-(Cyclohexylamino)-2,3-Dihydro-1H-Inden-1-One

(E)-2-Benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one is a synthetically derived organic compound, which serves as a selective inhibitor of specific protein kinases. It is synthesized through a series of organic reactions including condensation and amination, primarily in research laboratories focusing on medicinal chemistry. The mode of action involves the hindrance of kinase activity by binding to the enzyme's active site, thereby affecting intracellular signaling pathways. This type of targeted interference can lead to altered cell proliferation and apoptosis, and holds promise particularly in oncology research due to its potential to modulate cancer cell growth. Applications of (E)-2-Benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one are predominantly found in preclinical research stages, where it is utilized to investigate cellular mechanisms and potential therapeutic pathways. Through kinase inhibition, it is employed to understand disease processes and evaluate its feasibility as a lead compound in drug development projects.